In this session, you’ll learn how to:
-  Consider advantages and limitations of ICU vs Non-ICU settings in common clinical scenarios.
-  Approach level of care decisions from a shared decision making perspective among providers. 
-  Ensure patients and families understand motivations for level of care decisions.

John Dahdah, DO, Staff Physician, AdventHealth Tampa

In the keynote session, you’ll learn how to:
-  Start a conversation with anyone and build immediate rapport using the conversation blueprint
-  Start a conversation that breaks down barriers and social scripts, encouraging openness and trust; Understanding the power of psychological concept "The Swan Effect," and how it helps to stimulate connectedness through openness and vulnerability.

Robert L. DiGiovanni, DO, MACOI, President of the ACOI 2021-2022, Largo Medical Center

Susan M. Enright, DO, FACOI, Assistant Dean for Clerkship Education, MSUCOM

Vanessa Van Edwards, Founder of Science of People and Bestselling Author

In this session, you’ll learn how to:
-  Discuss new biologics and small molecule agents that have been FDA approved in the use of IBD over the past 2 years.
-  Discuss their respective mechanisms of action. 
-  Discuss appropriate session of when to use these new agents.

Susan Kais, MD, IBD Medical Director, Advent Health Orlando

In this session, you’ll learn how to:
-  Discuss advances in medical treatment of Hepatitis C.
-  Discuss advances in endoscopy.
-  Discuss advances in IBD treatment.

Michael Raphael, DO, Assistant Clinical Professor, MSU-COM, MSU-CHM

In this session, you’ll learn how to:
-  Learn to master diagnosis and treatment of GERD, nausea and vomiting.
-  Understand Pathophysiology of peptic ulcer disease and H Pylori, bloating and gallstone disease. 
-  Learn a systematic approach to the diagnosis and management of abdominal pain and the relationship to IBS - constipation or diarrhea predominance.

Charlene A. LePane, DO, FACOI, Gastroenterologist, AdventHealth

In this session, you’ll learn how to:
-  Diagnose pre-symptomatic Heart Failure (HF) at-risk patients; Distinguish HFeEF vs HFpEF.
-  Characterize the impact of SGLT2 inhibitors on HF risk among patients with Type 2 Diabetes. 
-  Discuss the putative mechanisms for cardio=protection associated with SGLT2 inhibitors.

Robert J. Chilton, DO, MACOI, Professor of Medicine, University of Texas Health Science Center

In this session, you’ll learn how to:
-  Identify patients at risk for fracture and develop a comfort level for interpreting diagnostic tools.
-  Identify effective treatment strategies based on mechanisms of action of the FDA approved medications for osteoporosis.
-  Develop an approach for long-term care, including frequency of monitoring, consideration of drug holidays and counseling regarding conservative measures to help decrease fracture risks.

Mark Vercel, DO, Assistant Professor of Clinical Medicine, University of South Dakota Sanford School of Medicine

In this session, you’ll learn how to:
-  Develop a rational approach to the diagnosis and evaluation of vasculitis and their mimics.
-  Differentiate potential vasculitis mimics based on the size of the blood vessel involved.
-  Identify the appropriate laboratory and radiographic evaluation in assessing for vasculitis and their common mimics.

Anisha Dua, MD, Director of the Vasculitis Center, Section of Rheumatology, Northwestern University Feinberg School of Medicine

In this session, you’ll learn how to:
-  Review the CASPAR criteria for psoriatic arthritis.
-  Describe the features of a typical psoriatic presentation.
-  Briefly discuss some of the most commonly used treatment options.

Arthur M. Mandelin, MD, PhD, Associate Professor of Medicine, Northwestern University Feinberg School of Medicine

In this session, you’ll learn how to:
-  Define an understand the causes of implicit bias.
-  Discuss the influence of stereotypes on implicit bias.
-  Explore the real world and healthcare implications of implicit bias.
-  Define and explore the terms belonging, breaking, bridging and othering.
-  Explore how bias leads to healthcare disparities.

Kellee L. Randle, DO, FACOI, CEO, Equity Ventures Plus, LLC

In this session, you’ll learn how to:
-  Pharmacologic approach to improve glycemic control in Type 2 diabetes.
-  Comparative data to improve glucose control with GLP receptors agonists and SGLT2 inhibitors. 
-  Discuss supporting data on cardiovascular risk reduction with both GLP receptor agonists and SGLT2 inhibitors.
-  Review data on the effectiveness of GLP receptor agonists and SGLT2 inhibitors on reducing obesity.
-  Learn new data on SGLT2 inhibitors and GLP receptor agonists pertaining to recusing renal end point.
-  Review data on the American Diabetes Association 2022 Guidelines and other organization’s statements pertaining to reducing cardiovascular and renal end points.

Jeffrey S. Freeman, DO, FACOI, Professor of Internal Medicine & Chairman of Division Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine

In this session, you’ll learn how to:
-  Discuss and understand symptoms that must be investigated in patients who have symptoms despite "well treated" hypothyroidism.
-  Discuss and understand alternative treatments of hypothyroidism symptoms.
-  Discuss and understand what can effect the thyroid blood tests and appropriate interpretation of the tests.

Jack L. Snitzer, DO, FACOI, Clinical Endocrinologist, TidalHealth Endocrinology